



**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

**REVIEWED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS**

**For the period from 01 January 2025 to 30 June 2025**



**TABLE OF CONTENTS**

<b><u>CONTENT</u></b>	<b><u>PAGE(S)</u></b>
STATEMENT OF THE BOARD OF MANAGEMENT AND BOARD OF GENERAL DIRECTORS	2 - 3
REVIEW REPORT ON INTERIM FINANCIAL INFORMATION	4 - 6
INTERIM CONSOLIDATED BALANCE SHEET	7 - 8
INTERIM CONSOLIDATED INCOME STATEMENT	9
INTERIM CONSOLIDATED CASH FLOW STATEMENT	10 - 11
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS	12 - 44

**STATEMENT OF THE BOARD OF MANAGEMENT  
AND BOARD OF GENERAL DIRECTORS**

The Board of Management and Board of General Directors of Vimedimex Medi-Pharma Joint Stock Company (hereinafter referred to as the "Company") presents this report together with the Company's reviewed interim consolidated financial statements for the period from 01 January 2025 to 30 June 2025.

**BOARD OF MANAGEMENT AND BOARD OF GENERAL DIRECTORS**

The members of the Board of Management, the Board of General Directors of the Company who held office for the period from 01 January 2025 to 30 June 2025 and up to the date of this report are as follows:

**Board of Management**

Mr. Le Xuan Tung	Chairman	
Mr. Trinh Thanh Giang	Vice Chairman	
Ms. Tran My Linh	Member	
Mr. Le Tri Dung	Member	
Mr. Le Tien Dung	Member	Appointed on 26 June 2025
Mr. Nguyen Minh Son	Member	Appointed on 26 June 2025
Mr. Nguyen Phan Trung Kien	Member	Appointed on 26 June 2025

**Board of General Directors**

Ms. Tran My Linh	General Director	
Ms. Do Thi Dong	Deputy General Director	
Mr. Be Cong Son	Deputy General Director	
Mr. Nguyen Bao Anh	Deputy General Director	
Mr. Le Tri Dung	Deputy General Director	
Mr. Nguyen Anh Tuan	Deputy General Director	Appointed on 07 March 2025

**Board of Supervisors**

Mr. Doan Duc Giang	Chief Supervisor	Appointed on 24 July 2025
Mr. Tran Hung Cuong	Chief Supervisor	Dismissed on 26 June 2025
Mr. Truong Duy Phong	Member	Appointed on 26 June 2025
Ms. Nguyen Thanh Thanh Binh	Member	Appointed on 26 June 2025
Mr. Nguyen Ba Tuan	Member	Dismissed on 26 June 2025

The legal representative of the Company during the accounting period and up to the date of this report is Ms. Tran My Linh - General Director.

**EVENTS AFTER THE BALANCE SHEET DATE**

The Board of Management and the Board of General Directors of the Company confirm that, except for the information disclosed in Note 35 to the Notes to the financial statements, there were no other events arising after 30 June 2025 that have a material impact and require adjustment to or disclosure in the interim financial statements for the period from 01 January 2025 to 30 June 2025 attached hereto.



**STATEMENT OF THE BOARD OF MANAGEMENT  
AND BOARD OF GENERAL DIRECTORS (CONT'D)**

**THE AUDITOR**

The accompanying consolidated financial statements from 01 January 2025 to 30 June 2025 have been reviewed by UHY Auditing and Consulting Company Limited.

**RESPONSIBILITY OF THE BOARD OF MANAGEMENT**

The Board of Management and Board of General Directors of the Company is responsible for preparing the consolidated financial statements which give a true and fair view of the Company's consolidated financial position as at 30 June 2025, as well as its consolidated results of operations and its consolidated cash flows for the period from 01 January 2025 to 30 June 2025. In preparing these interim consolidated financial statements, the Board of Management and Board of General Directors are required to:

- Select suitable accounting policies and apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting principles have been followed, subject to any material departures disclosed and explained in the interim consolidated financial statements;
- Design and implement an effective system of internal control to ensure preparation and fair presentation of the interim consolidated financial statements in order to limit risks and frauds; and
- Prepare the interim consolidated financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue its business.

The Board of Management and Board of General Directors confirm that the Company has complied with the above requirements in preparing the interim consolidated financial statements.

The Board of Management and Board of General Directors are responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the consolidated financial position of the Company and to ensure that the interim consolidated financial statements comply with Vietnamese Accounting Standards, Vietnamese Corporate Accounting Systems, and related legal regulations on the preparation and presentation of the interim consolidated financial statements. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Board of Management and Board of General Directors confirm that the Company has fully complied with its regulatory disclosure obligations as stipulated in Circular No. 96/2020/TT-BTC, dated 16 November 2020, issued by the Ministry of Finance, and Circular No. 68/2024/TT-BTC, dated 18 September 2024, amending and supplementing certain provisions of Circular No. 96/2020/TT-BTC concerning information disclosure in the securities market. The Company also ensures full compliance with the provisions of Decree No. 155/2020/ND-CP, dated 31 December 2020, issued by the Government, which provides detailed guidance on the implementation of specific provisions of the Securities Law. Furthermore, the Company adheres to the corporate governance requirements outlined in Circular No. 116/2020/TT-BTC, dated 31 December 2020, issued by the Ministry of Finance, which specifies governance standards applicable to public companies under Decree No. 155/2020/ND-CP.

For and on behalf of the Board of Management and Board of General Directors,



**Tran My Linh**  
**General Director**

Hanoi, 30 October 2025



No: 1169/2025/UHY-BCSX

## **REVIEW REPORT ON INTERIM FINANCIAL INFORMATION**

**To: Shareholders, Board of Management, Board of General Directors  
Vimedimex Medi-Pharma Joint Stock Company**

We have reviewed the accompanying interim consolidated financial statements of Vimedimex Medi-Pharma Joint Stock Company ("the Company"), which are prepared on 30 October 2025, from page 07 to page 44 that includes interim consolidated Balance sheet as at 30 June 2025, interim consolidated income statement and interim consolidated cash flow statement for the period from 01 January 2025 to 30 June 2025 and Notes to the interim consolidated financial statements.

### **Responsibilities of the Board of Management and Board of General Directors**

The Board of Management and Board of General Directors are responsible for the preparation and fair presentation of these interim consolidated financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and related legal regulations on the preparation and presentation of the interim consolidated financial statements, and for such internal control as the Board of Management and Board of General Directors determines is necessary to enable the preparation and presentation of the interim consolidated financial statements that are free from material misstatements, whether due to fraud or error.

### **Responsibilities of the Auditors**

Our responsibility is to express a conclusion on the interim consolidated financial statements based on the results of our review. We conducted our review in accordance with Vietnam Standards on Review Engagements No. 2410 - Review of interim financial information performed by the independent auditor of the entity.

A review of interim consolidated financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Basis for Qualified Opinion**

According to the Minutes of the Board of Management' Meeting No. 15/2025/BBHDQT-VMD dated 20 September 2025 of Vimedimex Pharmaceutical Joint Stock Company, the Board of Management requested the Board of General Directors to implement necessary measures to recover the losses incurred by the Company, totaling VND 131,797,789,132, comprising VND 48,139,850,632 of losses from office leasing cash flows of the buildings located at 246 Cong Quynh Street and 45 Vo Thi Sau Street for the period from 2021 to 2024; and VND 83,657,938,500 of understated pharmaceutical distribution service revenue of Vimedimex Binh Duong for the period from 2021 to 2024. As of the date of issuance of this Report, no results have been obtained from the implementation of the above-mentioned loss recovery measures in accordance with the said Minutes of the Board of Management's meeting. Therefore, we have not been able to assess the necessary adjustments (if any) that may affect the Company's interim consolidated financial statements.



## REVIEW REPORT ON INTERIM FINANCIAL INFORMATION (CONT'D)

### Qualified Opinion

Based on our review, except for the possible effects of the matters described in the “Basis for Qualified Opinion” section, nothing has come to our attention that causes us to believe that the accompanying interim consolidated financial statements do not present fairly, in all material respects, the financial position of Vimedimex Pharmaceutical Joint Stock Company as at 30 June 2025, and its results of operations and cash flows for the period from 01 January 2025 to 30 June 2025, in accordance with Vietnamese Accounting Standards, the Vietnamese Corporate Accounting System, and related legal requirements on the preparation and presentation of interim financial statements.

### Emphasis of Matter

We draw attention to Note 21 to the consolidated financial statements, which states that on 26 June 2025, pursuant to Resolution No. 01/2025/NQ-DHDCD-VMD of the General Meeting of Shareholders of Vimedimex Pharmaceutical Joint Stock Company, the General Meeting approved the revocation of 2,284,950 VMD shares, representing 14.8% of the charter capital of Vimedimex Pharmaceutical Joint Stock Company, and the cancellation of shareholder status of Ms. Nguyen Ngoc Dung, Ms. Tran Thi Doan Trang, and Mr. Tran Kien Cuong, effective from 01 January 2025. The resolution also confirmed the shareholder status of Vimedimex Pharmaceutical Group Joint Stock Company as the holder of 2,284,950 VMD shares, equivalent to 14.8% of the charter capital of Vimedimex Pharmaceutical Joint Stock Company, effective from 01 January 2025.

We draw attention to Note 35 to the consolidated financial statements, which discloses the following matters:

- The Board of Management of Vimedimex Pharmaceutical Joint Stock Company (VMD) requested the Board of General Directors to implement measures to assist in the recovery of losses incurred by Vimedimex Pharmaceutical Group Joint Stock Company (VMG), a related party of VMD. These losses include fund transfers from VMG through VMD, followed by cash withdrawals and bank transfers totaling VND 343,738,865,391 (*during the period from 15 April 2021 to 30 January 2023*), and a receivable from Ms. Nguyen Ngoc Dung amounting to VND 193 billion, representing cash withdrawn in 2022 but not yet repaid (*according to the Minutes of the Board of Directors' Meeting No. 136/2024/BB-VMG dated 31 December 2024 of VMG, the Board of Directors of VMG approved that VMG would be responsible for recovering the doubtful receivable of VND 193 billion related to Ms. Nguyen Ngoc Dung on behalf of VMD, and accordingly, VMD would no longer have any obligation to repay the VND 193 billion liability to VMG.*)
- Certain individuals in executive management positions at both VMG and VMD directed cash inflows and outflows totaling VND 252,353,295,174, and instructed Mr. Nguyen Tien Manh to withdraw VND 76,978,900,000, resulting in a total loss of VND 328,400,200,202 for VMG during the period from 19 April 2021 to 24 October 2024.

We draw attention to Note 36 to the consolidated financial statements, which describes that the Company has cooperated with certain investors to develop the Citilight Building located at 45 Vo Thi Sau Street, District 1 (former), Ho Chi Minh City. Upon completion, the Company allocated floor areas to investors in accordance with the proportions stipulated in the business cooperation contracts. On 24 February 2020, the Company issued Official Letter No. 1421/2020/CV-VMD providing official information to the press agencies regarding the Citilight Building at 45 Vo Thi Sau Street. Accordingly, the Company temporarily suspended activities related to the distribution of rental income from the commercial areas of the Citilight Building, as well as other related activities, in order to conduct an audit of the investment, capital contribution, operation, and management of the Citilight Building. The Company and the investors are currently in discussions to reach an agreement on the above matters. Consequently, this event may result in future economic benefits and/or obligations for the Company.

Our qualified conclusion is not modified in respect of this matter.

## REVIEW REPORT ON INTERIM FINANCIAL INFORMATION (CONT'D)

### Other Matter

The interim consolidated financial statements for the period from 01 January 2024 to 30 June 2024 were reviewed, and the consolidated financial statements for the financial year ended 31 December 2024 were audited by another independent auditor and audit firm. That auditor and audit firm expressed an unqualified conclusion on the interim consolidated financial statements for the period from 01 January 2024 to 30 June 2024 in their Review Report No. 0208.2/2024/BCSX/IAV dated 29 August 2024, and expressed an unmodified opinion on the separate financial statements for the financial year ended 31 December 2024 in their Audit Report No. 0208.2/2024/BCTC/IAV dated 31 March 2025.



**Pham Gia Dat**

**Deputy General Director**

Auditor's Practicing Certificate

No. 0798-2023-112-1

*For and on behalf of*

**UHY AUDITING AND CONSULTING COMPANY LIMITED**

*Hanoi, 30 October 2025*



For the period from 01/01/2025 to 30/06/2025

**INTERIM CONSOLIDATED BALANCE SHEET**

*As at 30 June 2025*

ASSETS	Code	Note	30/06/2025 VND	01/01/2025 VND
<b>CURRENT ASSETS</b>	<b>100</b>		<b>921,876,569,442</b>	<b>976,302,697,513</b>
<b>Cash and cash equivalent</b>	<b>110</b>	<b>5</b>	<b>124,646,234,063</b>	<b>301,121,593,123</b>
Cash	111		102,346,234,063	116,921,593,123
Cash equivalents	112		22,300,000,000	184,200,000,000
<b>Short-term investments</b>	<b>120</b>	<b>15</b>	<b>242,580,457,820</b>	<b>33,960,457,820</b>
Held-to-maturity investments	123		242,580,457,820	33,960,457,820
<b>Current accounts receivables</b>	<b>130</b>		<b>446,278,952,470</b>	<b>524,739,618,892</b>
Short-term trade receivables	131	7	345,695,933,744	404,257,621,340
Short-term advances to suppliers	132	8	14,617,856,577	17,931,947,382
Other short-term receivables	136	9	187,123,856,862	206,275,405,076
Provision for doubtful short-term receivables	137	7, 8, 9	(101,190,880,688)	(103,757,540,881)
Shortage of assets awaiting resolution	139		32,185,975	32,185,975
<b>Inventories</b>	<b>140</b>	<b>10</b>	<b>78,747,297,664</b>	<b>84,863,827,274</b>
Inventories	141		83,449,326,551	89,806,109,642
Provision for devaluation of inventories	149		(4,702,028,887)	(4,942,282,368)
<b>Other current assets</b>	<b>150</b>		<b>29,623,627,425</b>	<b>31,617,200,404</b>
Short-term prepaid expenses	151	6	259,585,457	1,705,968,364
Value-added tax deductible	152		29,349,948,734	29,897,138,806
Tax and other receivables from the State budget	153	20	14,093,234	14,093,234
<b>NON-CURRENT ASSETS</b>	<b>200</b>		<b>211,137,904,990</b>	<b>221,152,127,047</b>
<b>Long-term receivables</b>	<b>210</b>		<b>5,824,576,965</b>	<b>6,156,226,965</b>
Other long-term receivables	216	9	5,824,576,965	6,156,226,965
<b>Fixed assets</b>	<b>220</b>		<b>101,214,851,445</b>	<b>108,703,732,854</b>
Tangible fixed assets	221	11	72,089,085,839	76,876,286,555
- Cost	222		202,769,249,611	202,032,403,350
- Accumulated depreciation	223		(130,680,163,772)	(125,156,116,795)
Intangible fixed assets	227	12	29,125,765,606	31,827,446,299
- Cost	228		45,801,634,957	45,801,634,957
- Accumulated amortization	229		(16,675,869,351)	(13,974,188,658)
<b>Investment properties</b>	<b>230</b>	<b>13</b>	<b>59,276,308,205</b>	<b>60,742,297,625</b>
- Cost	231		103,327,212,088	103,327,212,088
- Accumulated depreciation	232		(44,050,903,883)	(42,584,914,463)
<b>Long-term assets in progress</b>	<b>240</b>		<b>34,658,221,377</b>	<b>33,904,886,333</b>
Construction in progress	242	14	34,658,221,377	33,904,886,333
<b>Long-term investments</b>	<b>250</b>	<b>15</b>	<b>8,991,256,348</b>	<b>8,991,256,348</b>
Investment in other entities	253		18,730,978,694	18,730,978,694
Provision for long-term investments	254		(10,799,722,346)	(10,799,722,346)
Held-to-maturity investments	255		1,060,000,000	1,060,000,000
<b>Other long-term assets</b>	<b>260</b>		<b>1,172,690,650</b>	<b>2,653,726,922</b>
Long-term prepaid expenses	261	6	1,172,690,650	2,653,726,922
<b>TOTAL ASSETS</b>	<b>270</b>		<b>1,133,014,474,432</b>	<b>1,197,454,824,560</b>

For the period from 01/01/2025 to 30/06/2025

**INTERIM CONSOLIDATED BALANCE SHEET (CONT'D)**

As at 30 June 2025

RESOURCES	Code	Note	30/06/2025 VND	01/01/2025 VND
<b>LIABILITIES</b>	<b>300</b>		<b>707,397,414,564</b>	<b>780,800,416,359</b>
<b>Current liabilities</b>	<b>310</b>		<b>688,650,623,897</b>	<b>762,330,823,967</b>
Short-term trade payables	311	16	520,162,827,032	598,383,232,938
Short-term advances from customers	312	18	25,864,011,437	9,760,266,298
Tax and other payables to the State budget	313	20	2,515,340,805	5,930,793,460
Payables to employees	314		2,447,902,291	2,595,694,676
Short-term accrued expenses	315	19	939,918,883	2,132,025,476
Other short-term payables	319	17	131,636,012,303	138,444,199,973
Bonus and welfare fund	322		5,084,611,146	5,084,611,146
<b>Non-current liabilities</b>	<b>330</b>		<b>18,746,790,667</b>	<b>18,469,592,392</b>
Other long-term liabilities	337	19	18,746,790,667	18,469,592,392
<b>OWNERS' EQUITY</b>	<b>400</b>		<b>425,617,059,868</b>	<b>416,654,408,201</b>
<b>Capital</b>	<b>410</b>	<b>21</b>	<b>423,693,599,928</b>	<b>414,730,948,261</b>
Share capital	411		154,402,680,000	154,402,680,000
- Shares with voting rights	411a		154,402,680,000	154,402,680,000
Share premium	412		114,168,390,910	114,168,390,910
Investment and development fund	418		33,732,320,126	33,732,320,126
Other equity funds	420		7,338,446,765	7,338,446,765
Retained earnings	421		35,610,161,856	25,685,434,763
- Accumulated losses by the end of prior year	421a		25,685,434,763	1,938,945,480
- Retained earnings for the current period	421b		9,924,727,093	23,746,489,283
Non-controlling interests	429		78,441,600,271	79,403,675,697
<b>Other funds</b>	<b>430</b>		<b>1,923,459,940</b>	<b>1,923,459,940</b>
Funding source	431		1,923,459,940	1,923,459,940
<b>TOTAL LIABILITIES AND OWNERS' EQUITY</b>	<b>440</b>		<b>1,133,014,474,432</b>	<b>1,197,454,824,560</b>

Ha Noi, 30 October 2025



**Tran Thi Thanh Binh**  
Preparer



**Nguyen Thi Thu Dung**  
Chief Accountant



**Tran My Linh**  
General Director




For the period from 01/01/2025 to 30/06/2025

**INTERIM CONSOLIDATED INCOME STATEMENT**


*For the period from 01 January 2025 to 30 June 2025*

ITEMS	Code	Note	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
<b>Revenue from sale of goods and rendering of services</b>	<b>01</b>	<b>23</b>	<b>544,218,089,972</b>	<b>613,894,954,672</b>
Deductions	02	24	7,450,304,812	622,629,178
<b>Net revenue from sale of goods and rendering of services</b>	<b>10</b>		<b>536,767,785,160</b>	<b>613,272,325,494</b>
Cost of goods sold and services rendered	11	25	491,085,057,781	556,477,558,259
<b>Gross profit from sale of goods and rendering of services</b>	<b>20</b>		<b>45,682,727,379</b>	<b>56,794,767,235</b>
Finance income	21	26	5,524,033,033	3,217,510,841
Finance expense	22	27	3,095,733,665	6,386,953,590
- In which: Interest expenses	23		-	2,281,941,510
Selling expenses	25	28	36,015,675,230	37,557,200,119
General and administrative expenses	26	28	10,561,744,881	9,019,763,800
<b>Operating profit</b>	<b>30</b>		<b>1,533,606,636</b>	<b>7,048,360,567</b>
Other income	31		10,387,052,514	5,880,965
Other expenses	32	29	294,601,096	69,634,003
<b>Other profit</b>	<b>40</b>		<b>10,092,451,418</b>	<b>(63,753,038)</b>
<b>Accounting profit before tax</b>	<b>50</b>		<b>11,626,058,054</b>	<b>6,984,607,529</b>
Current corporate income tax expense	51	31	2,663,406,387	1,919,934,404
<b>Net profit after tax</b>	<b>60</b>		<b>8,962,651,667</b>	<b>5,064,673,125</b>
Net profit after tax attributable to shareholders of the parent	61		9,924,727,093	5,271,412,072
Net profit after tax attributable to non-controlling interests	62		(962,075,426)	(206,738,947)
<b>Basic earnings per share</b>	<b>70</b>	<b>32</b>	<b>643</b>	<b>341</b>
<b>Diluted earnings per share</b>	<b>71</b>	<b>32</b>	<b>643</b>	<b>341</b>

Ha Noi, 30 October 2025

  
Tran Thi Thanh Binh  
Preparer

  
Nguyen Thi Thu Dung  
Chief Accountant

  
Tran My Linh  
General Director



For the period from 01/01/2025 to 30/06/2025

**INTERIM CONSOLIDATED CASH FLOW STATEMENT**

*(Applying indirect method)*

*For the period from 01 January 2025 to 30 June 2025*

ITEMS	Codes Note	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
<b>I. Cash flows from operating activities</b>			
<i>Profit before tax</i>	<b>01</b>	<b>11,626,058,054</b>	<b>6,984,607,529</b>
<i>Adjustments for:</i>			
Depreciation and amortization	02	9,691,717,090	9,672,044,808
Reversal of provisions	03	(2,806,913,674)	(1,174,802,843)
Foreign exchange (gains)/losses arisen from revaluation of monetary accounts denominated in foreign currency	04	2,264,006,764	36,955,253
(Profits)/losses from investing activities	05	(5,507,774,180)	(3,208,630,736)
Interest expenses	06	-	2,281,941,510
<b>Operating profit/(loss) before changes in working capital</b>	<b>08</b>	<b>15,267,094,054</b>	<b>14,592,115,521</b>
Increase, decrease in receivables	09	84,931,697,861	249,952,200,976
Increase, decrease in inventories	10	6,356,783,091	72,277,866,754
Increase, decrease in payables (excluding interest, corporate income tax)	11	(73,307,910,629)	(390,791,783,558)
Increase, decrease in prepaid expenses	12	2,958,919,179	3,414,551,154
Interest paid	14	-	(2,281,941,510)
Corporate income tax paid	15	(5,335,835,096)	(4,567,812,132)
<b>Net cash flows from/(used in) operating activities</b>	<b>20</b>	<b>30,870,748,460</b>	<b>(57,404,802,795)</b>
<b>II. Cash flows from investing activities</b>			
Purchase and construction of fixed assets and other long-term assets	21	(1,490,181,305)	(6,568,556,187)
Loans to other entities and payments for purchase of debt instruments of other entities	23	(208,620,000,000)	-
Collections from borrowers and proceeds from sale of debt instruments of other entities	24	-	7,650,000,000
Interest and dividends received	27	2,764,073,785	3,878,412,742
<b>Net cash from investing activities</b>	<b>30</b>	<b>(207,346,107,520)</b>	<b>4,959,856,555</b>
<b>III. Cash flows from financing activities</b>			
Drawdown of borrowings	33	-	293,500,000,000
Repayment of borrowings	34	-	(203,000,000,000)
<b>Net cash flows (used in) financing activities</b>	<b>40</b>	<b>-</b>	<b>90,500,000,000</b>



For the period from 01/01/2025 to 30/06/2025

**INTERIM CONSOLIDATED CASH FLOW STATEMENT (CONT'D)**

*(Applying indirect method)*

*For the period from 01 January 2025 to 30 June 2025*

ITEMS	Codes	Note	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
			VND	VND
Net (decrease)/increase in cash for the period	50		(176,475,359,060)	38,055,053,760
Cash and cash equivalents at the beginning of the year	60	5	301,121,593,123	209,806,173,673
Impact of exchange rate fluctuation	61		-	-
Cash and cash equivalents at the end of the period	70	5	124,646,234,063	247,861,227,433

*Hanoi, 30 October 2025*



**Tran Thi Thanh Binh**  
Preparer



**Nguyen Thi Thu Dung**  
Chief Accountant



**Tran My Linh**  
General Director

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**1. COMPANY OVERVIEW**

**1.1 OWNERSHIP STRUCTURE**

Vimedimex Medi-Pharma Joint Stock Company established and operating under Enterprise Registration Certificate No. 0300479760, initially issued by Hanoi City Department of Finance (formerly Department of Planning and Investment) on 12 June 2006 and amended for the 36th time on 27 March 2023.

The registered head office of the Company is located on the 8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam.

The Company's charter capital as stated in the Enterprise Registration Certificate is VND 154,402,680,000 (*One hundred fifty-four billion, four hundred two million, six hundred eighty thousand*). Total number of shares is 15,440,268 shares, par value of 01 (one) share is VND 10,000.

The number of employees of the Company as at 30 June 2025 was 31 people (as at 01 January 2025: 33 people).

**1.2 BUSINESS LINES AND PRINCIPAL ACTIVITIES**

The Company operates principally in the fields of trading, services, and real estate business.

The Company's principal business activities include:

- Acting as an entrusted agent for import and export services;
- Leasing office buildings and warehouses.

**1.3 NORMAL OPERATING CYCLE**

The Company's normal operating cycle is carried out within a period not exceeding 12 months.

**1.4 COMPANY STRUCTURE**

As at 30 June 2025, the Company has the following subsidiaries:

Company name	Place of establishment and operation	Ownership ratio	Voting rights ratio	Main operation field
Vimedimex Pharmaceutical LLC.,	Ho Chi Minh	100%	100%	Wholesale of pharmaceutical products, pharmaceuticals, functional foods, medical equipment, cosmetics, and consumer goods for mothers and children
Vimedimex Binh Duong One Member LLC.,	Binh Duong	100%	100%	Wholesale of pharmaceutical products, pharmaceuticals, functional foods, medical equipment, cosmetics, and consumer goods for mothers and children



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**1. COMPANY OVERVIEW (CONT'D)**

**1.4 COMPANY STRUCTURE (CONT'D)**

Vimedimex Pharmaceutical Distribution Center LLC.,	Ha Noi	55,6%	55,6%	Wholesale and retail of pharmaceutical products, business cooperation, medical examination and treatment
Vimedimex Medicinal Plant One Member LLC., (*)	Da Lat	100%	100%	Cultivation of medicinal plants

(\*): On 14 May 2020, the Board of Management of the Company resolved to dissolve Vimedimex Herbal One Member Limited Liability Company, pursuant to the Minutes of the Parent Company's Board of Management's meeting No. 45-1/BB-VMD. As at the date of preparation of these consolidated financial statements, this subsidiary is in the process of dissolution in accordance with the provisions of law. The financial statements of this subsidiary were prepared on the going concern basis and were included in the Company's consolidated financial statements. As the total assets of the subsidiary as at 31 December 2025 amounted to VND 586 million, the Board of Management and the Board of General Directors of the Company assessed that the non-determination of the subsidiary's fair value in preparing the consolidated financial statements does not have a material impact on the financial information presented in the consolidated financial statements.

**2. ACCOUNTNG PERIOD, ACCOUNTING CURRENCY**

**2.1 ACCOUNTNG PERIOD**

The accounting period of the Company begins from 01 January to 30 June.

The accompanying consolidated financial statements were prepared for the period from 01 January 2025 to 30 June 2025.

**2.2 ACCOUNTING CURRENCY**

The accounting currency used in accounting records and in the preparation of the interim consolidated financial statements is Vietnamese dong (VND).

**3. APPLIED ACCOUNTING STANDARDS AND REGULATIONS**

**3.1 STATEMENT OF COMPLIANCE WITH ACCOUNTING STANDARDS AND REGULATIONS**

The interim consolidated financial statements for the period from 01 January 2025 to 30 June 2025 are prepared in accordance with the Vietnamese Corporate Accounting Standards issued together with Circular No. 200/2014/TT-BTC issued by the Ministry of Finance on 22 December 2014, Circular No. 53/2016/TT-BTC dated 21 March 2016 of the Ministry of Finance on amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC and Circular No. 202/2014/TT-BTC dated 22 December 2014 on guidance on preparing the consolidated financial statements of the Ministry of Finance.

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**3. APPLIED ACCOUNTING STANDARDS AND REGULATIONS (CONT'D)**

**3.1 STATEMENT OF COMPLIANCE WITH ACCOUNTING STANDARDS AND REGULATIONS (CONT'D)**

The Board of Management and Board of General Directors of the Company ensure full compliance with requirements of Vietnamese Accounting Standards and Vietnamese Corporate Accounting System for the preparation of the consolidated financial statements.

**3.2 BASIS OF THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS PREPARATION**

The consolidated financial statements for the period from 01 January 2025 to 30 June 2025, of Vimedimex Medi-Pharma Joint Stock Company are prepared based on the consolidation of the financial statements of the parent company and its subsidiaries.

The business performance of subsidiaries that were acquired or disposed of during the year is presented in the consolidated income statement from the acquisition date or up to the date of disposal of the investment in that subsidiary.

Where necessary, the financial statements of the subsidiaries are adjusted so that the accounting policies applied at the Company and its subsidiaries are consistent.

Transactions and balances between the parent company and its subsidiaries are eliminated when preparing the interim consolidated financial statements.

The interests of non-controlling shareholders in the net assets of the consolidated subsidiaries are presented as a separate line item within equity.

**3.3 ACCOUNTING METHOD**

The Company applies the computerized accounting system.

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The following are the significant accounting policies applied by the Company in preparing its interim consolidated financial statements for the period from 01 January 2025 to 30 June 2025:

**4.1 CHANGES IN ACCOUNTING POLICIES AND NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

The accounting policies adopted for the period from 01 January 2025 to 30 June 2025 are consistent with the accounting policies being prepared for the consolidated financial statements for the financial year end 31 December 2024.

**4.2 ACCOUNTING ESTIMATES**

The preparation of interim consolidated financial statements in conformity with Vietnamese Accounting Standards requires the Board of General Directors to make estimates and assumptions that affect reported amounts of liabilities, assets, and the disclosure of contingent liabilities and assets as at the reporting date, as well as the reported amounts of revenue and expenses during financial year (operating period). Actual results may differ from those estimates and assumptions.

**4.3 CASH AND CASH EQUIVALENTS**

Cash and cash equivalents include cash on hand, demand deposits at banks, deposits, and guarantees, as well as short-term investments with an original maturity of no more than three months, which are highly liquid, easily convertible into a known amount of cash, and subject to insignificant risk of changes in value.



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

**4.4 RECEIVABLES AND PROVISIONS FOR DOUBTFUL DEBTS**

Receivables are presented at their book value less provision for doubtful debts.

The classification of receivables is performed according to the following principles:

- Trade receivables reflect amounts owed from customers arising from commercial transactions between the Company and independent buyers.
- Other receivables reflect amounts owed that are non-commercial and unrelated to buying and selling transactions.
- The provision for doubtful debts is made by the Company for receivables that are overdue for payment as stipulated in economic contracts, contractual commitments, or debt commitments, where the Company has made several collection attempts but has not yet recovered the debts. The determination of the overdue period is based on the original payment term under the initial sales contract, without considering any debt extension agreements between the parties. The provision is also made for receivables not yet due but where the debtor is bankrupt, undergoing dissolution procedures, missing, or has absconded. The provision is reversed when the debts are recovered.
- Any increase or decrease in the provision for doubtful debts at the financial statement closing date is recorded as general and administrative expenses.

**4.5 INVENTORIES**

Inventory is determined based on the lower of cost and net realizable value. The cost of inventory includes all expenses incurred to acquire the inventory at its current location and condition, including: purchase price, non-recoverable taxes, transportation costs, loading and unloading expenses, storage costs during the procurement process, standard shrinkage, and other costs directly attributable to the acquisition of inventory.

Net realisable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

The company applies the perpetual inventory method for accounting for inventory. The cost of goods sold is calculated using the weighted average method.

The company's provision for inventory devaluation is established in accordance with current regulations. Accordingly, the company recognizes an inventory write-down in cases where the inventory is obsolete or of poor quality, and when the carrying amount of the inventory exceeds its net realizable value at the end of the accounting period.

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

**4.6 PREPAID EXPENSES**

Long-term prepaid expenses include expenses incurred during the financial year that relate to multiple periods of production and business activities. These expenses are recorded as long-term prepaid expenses and are gradually allocated to the business results over several periods.

The calculation and allocation of long-term prepaid expenses into production and business costs in each accounting period is based on the nature and level of each type of expense to select a reasonable allocation method and criteria.

The Company's prepaid expenses include the value of tools and supplies awaiting allocation, fixed asset repair costs, office repair and completion costs and other costs, which are considered to be able to provide future economic benefits to the Company. These costs are capitalized as prepayments and allocated to the consolidated income statement using the straight-line method in accordance with current regulations.

**4.7 TANGIBLE FIXED ASSETS AND DEPRECIATION**

Tangible fixed assets are recorded at cost, reflected on the Consolidated Balance Sheet according to the indicators of cost, accumulated depreciation and carrying amount.

The recognition of tangible fixed assets and depreciation of fixed assets are carried out in accordance with Vietnamese Accounting Standard No. 03 - Tangible Fixed Assets, Circular No. 200/2014/TT-BTC dated 22 December 2014 of the Ministry of Finance guiding the corporate accounting system.

Tangible fixed assets are presented at cost and accumulated depreciation. The cost of tangible fixed assets comprises their purchase price and any directly attributable costs of bringing the assets to its working condition and location to be ready for use. The costs of fixed assets constructed by contractors are the finalized cost of the work, directly related expenses and registration fee (if any).

Depreciation is calculated on a straight-line basis for all assets over their estimated useful lives. The principal annual depreciation rates in use are as follows:

<b>Assets</b>	<b>Useful lives (years)</b>
- Buildings and structures	05 - 25
- Machinery, equipment	05 - 08
- Motor vehicles, transmission	06 - 10
- Office equipment	03 - 08
- Perennial garden	06
- Other fixed assets	04 - 25



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

**4.8 INTANGIBLE FIXED ASSETS AND AMORTISATION**

Intangible fixed assets are stated at cost, recorded in balance sheet under initial cost of acquire, accumulated amortisation and carrying amount.

Amortisation and the recording of intangible fixed assets are conducted in accordance with Vietnamese Accounting Standard No. 04 – Intangible fixed assets, Circular No. 200/2014/TT-BTC dated 22 December 2014, of the Ministry of Finance.

The initial cost of intangible fixed assets encompasses all expenses that the Company incurs from the time the asset is acquired until it is available for use. Production and business expenses are recognised in the period for expenses associated with intangible fixed assets that are incurred after initial recognition, unless these expenses are associated with a specific intangible fixed asset and enhance the economic benefits of these assets.

Accumulated amortisation and cost are the declared values of fixed assets.

**4.9 INVESTMENT PROPERTY**

Investment property includes land use rights, buildings, portions of buildings, or infrastructure owned by the Company for the purpose of earning rental income or capital appreciation. Investment properties are recorded at cost, less accumulated depreciation. The cost of investment property comprises all expenses incurred by the Company or the fair value of consideration given in exchange to acquire the investment property up to the date of purchase or completion of construction.

Subsequent expenses related to investment property are recognized as expenses unless it is certain that these costs will generate additional future economic benefits beyond the initially assessed level of performance. In such cases, the expenses are capitalized as an increase in the cost of investment property.

When an investment property is sold, its cost and accumulated depreciation are derecognized, and any resulting gain or loss is recorded as income or expense in the period.

A transfer from owner-occupied property or inventory to investment property occurs only when the owner ceases to use the asset and starts leasing it out to another party or upon the completion of construction. Conversely, a transfer from investment property to owner-occupied property or inventory happens only when the owner begins using the asset or repurposes it for sale. Such transfers do not affect the cost or carrying amount of the property as of the transfer date.

Investment properties held for rental purposes are depreciated using the straight-line method based on their estimated useful lives. The estimated useful lives of specific investment properties are as follows:

Assets	Useful life (year)
- Building, structure and property	24 - 25
- Land use rights	50

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

**4.10 FINANCIAL INVESTMENTS**

*Held-to-maturity financial investments* include: Term bank deposits, bonds, preferred shares that the issuer is obligated to repurchase at a specific future date, loans, and other investments held to maturity for the purpose of earning periodic interest.

*Investments in other entities* refer to equity investments in entities where the Company does not have control, joint control, or significant influence over the investee.

***Provision for impairment of investments***

Provision for impairment of investments in equity instruments of other entities is made at the time of preparation of the separate financial statements when such investments show a decline compared to their original cost. The Company makes provision for impairment as follows:

- The provision is based on the market value of the shares for investments in listed shares or for which the fair value of the investment is reliably determined.
- Provisions are made for investments whose fair value cannot be determined at the reporting date in an amount that is equivalent to the difference between the actual capital contributions of the parties at other entities and the actual equity multiplied by the company's capital contribution ratio in comparison to the total actual capital contributions of the parties at other entities.

In case an investment entity is obligated to prepare the consolidation of financial statements, the foundation for establishing the loss provision is the consolidated financial statements.

Adjustments for provision in financial investments to other entities must be identified at the closing date of financial statements and recognized in the income statement as financial expenses or income.

**4.11 PAYABLES AND ACCRUED EXPENSES**

Payables and accrued expenses are recognized for amounts to be paid in the future relating to goods and services received. Accrued expenses are recognized based on reasonable estimates of the amounts payable.

The classification of payables into trade payables, accrued expenses, and other payables is made according to the following principles:

- Trade payables represent commercial liabilities arising from purchases of goods, services, or assets from independent suppliers, including amounts payable for imports through entrusted importers;
- Accrued expenses represent amounts payable for goods or services received from suppliers or provided to customers but not yet paid, due to the absence of invoices or insufficient supporting documents, and include accruals for employee benefits such as unused annual leave and other provisions for production and business expenses;
- Other payables represent non-commercial liabilities that are not related to transactions for the purchase or sale of goods and services.



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

**4.12 OWNER'S EQUITY**

Owner's equity is acknowledged in relation to the capital contributed to the entity by the owner.

The performance of the company is reflected in the retained earnings, which include the profit, loss after corporate income tax, and distributable to the shareholder. The distributable accumulated earnings are required to not exceed the undistributed profit after tax in the interim consolidated financial statements after the impact of profits recorded from bargain purchases has been excluded. Retained earnings are the property of shareholders; however, the decision to retain them, distribute them or distributable amount to shareholders through dividends will be determined by the company's charter, comply with Vietnamese law and approved by the General Meeting of Shareholders.

**4.13 REVENUE**

Revenue is recognised when it is probable that the economic benefits will flow to the company and can be reliably measured. Net revenue is measured at the fair value of the amounts received or receivable after deducting trade discounts, sales rebates, and sales returns. Revenue is recognized when the following conditions are simultaneously satisfied:

***Revenue from sale of goods***

Revenue from sale of goods is recognised when the following criteria are met:

- Most of the risks and benefits associated with ownership of the product or goods have been transferred to the buyer;
- The Company no longer holds the same management of the goods as the owner of the goods or the right to control the goods;
- Future economic benefits can be measured reliably;
- Future economic benefits will flow to the entity or captured;
- Costs associated with sales can be identified.

***Revenue from rendering of services***

Revenue from rendering of services is recognised when the following criteria are met:

- Revenue is determined with relative certainty;
- Ability to derive economic benefits from the transaction of providing such services;
- Determine the part of work completed on the date of preparation of the Balance Sheet;
- Determine the costs incurred for the transaction and the cost to complete the transaction to provide that service.

The extent of service work finished is established by the approach used to evaluate the completed tasks.

***Revenue from financial activities***

Revenue arising from interest, royalties, dividends, profit distributions, and other financial income is recognized when both of the following conditions are satisfied:

- Ability to obtain economic benefits;
- Revenue is determined with relative certainty.

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

**4.14 COST OF GOODS SOLD**

The cost of goods sold for the year is documented in alignment with the revenue generated during that period ensuring adherence to the principle of prudence. Instances of material loss surpassing the standards, expenses, exceeding the usual threshold, and lost inventory after accounting for the liability of the pertinent group or individual are comprehensively and swiftly documented in the cost of goods sold for the period.

**4.15 FINANCIAL EXPENSES**

Financial expenses include losses incurred from foreign currency sales, foreign exchange losses, and other related items.

These expenses are recorded at their total amounts incurred during the period and are not offset against financial income.

**4.16 TAXATION**

Input value-added tax (VAT) is accounted for using the deduction method.

The current tax payable is calculated based on taxable income for the year. Taxable income may differ from accounting profit before tax presented in the income statement as it excludes income or expenses that are taxable or deductible in different periods (including any carried-forward tax losses, if applicable) and does not include non-taxable items or non-deductible expenses.

The current CIT rate is 20%.

Taxable profit is determined based on the operating results, adjusted for non-taxable income and non-deductible expenses. The calculation of taxable profit and current CIT expense is based on the prevailing tax regulations. However, these regulations may change over time, and the final determination depends on the results of audits conducted by the relevant tax authorities.

Other types of taxes are implemented in accordance with the prevailing regulations of the State.

**4.17 RELATED PARTIES**

A party is related to the Company if it has the ability to control the Company or exercise significant influence over the Company in making financial and operating decisions. Related parties include:

- Enterprises have the right to control or be directly or indirectly controlled by one or more intermediaries, or under the common control with companies, including joint ventures, co-controlled business establishments and associates;
- Individuals have the right to vote in reported enterprises, having a significant influence directly or indirectly on these enterprises, key executives have the authority and responsibility for making plan, management and controlling activities of the Company, including close family members of these individuals;
- Enterprises owned by individuals, having direct or indirect voting rights or having a significant influence on the business.

When considering each relationship of related parties, the nature of the relationship is paid special attention to, not merely its legal form. All transactions and balances are presented hereunder.



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**5. CASH AND CASH EQUIVALENTS**

	<b>30/06/2025</b>	<b>01/01/2025</b>
	<b>VND</b>	<b>VND</b>
- Cash on hand	3,058,141,861	306,441
- Non-term bank deposits	99,288,092,202	116,921,286,682
- Cash equivalents (*)	22,300,000,000	184,200,000,000
	<b>124,646,234,063</b>	<b>301,121,593,123</b>

(\*): Term deposits from 01 to 03 months at commercial banks.

**6. PREPAID EXPENSES**

	<b>30/06/2025</b>	<b>01/01/2025</b>
	<b>VND</b>	<b>VND</b>
<b>Short-term</b>	<b>259,585,457</b>	<b>1,705,968,364</b>
- Tools and equipments	1,762,197	59,902,541
- Repair costs of assets	27,383,083	154,196,882
- Others	230,440,177	1,491,868,941
<b>Long-term</b>	<b>1,172,690,650</b>	<b>2,653,726,922</b>
- Prepaid expenses for operating fixed assets	-	144,225,661
- Tools and equipment used	349,521,058	650,224,517
- Printing and marketing expenses	7,551,852	133,622,547
- Repairment of fixed assets	664,342,315	1,527,737,469
- Others	151,275,425	197,916,728
	<b>1,432,276,107</b>	<b>4,359,695,286</b>

**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)***(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)***7. SHORT-TERM TRADE RECEIVABLES**

	30/06/2025		01/01/2025	
	Balance VND	Provision VND	Balance VND	Provision VND
- Bach Mai Hospital Hanoi	18,007,963,950	-	16,376,633,489	-
- Cho Ray Hospital	8,062,462,317	-	8,128,695,457	-
- Phat Nhu Quan Pharmaceutical Co., Ltd.	30,682,293,032	(30,682,293,032)	30,682,293,032	(30,682,293,032)
- BV Pharma Joint Stock Company	25,625,540,221	-	25,542,126,659	-
- Thy Thu Pharmaceutical Co., Ltd.	8,962,462,619	-	28,121,999,397	-
- Vietnam Trade and Pharmaceutical Joint Stock Company	18,574,103,597	(18,574,103,597)	18,574,103,597	(18,574,103,597)
- Ngoc Linh Trang Pharmaceutical Trading Co., Ltd.	16,776,318,532	(16,630,107,729)	16,776,318,532	(16,630,107,729)
- Vinpharco Pharmaceutical Joint Stock Company	13,637,924,769	(13,023,567,825)	13,637,924,769	(13,023,567,825)
- Others	205,366,864,707	(18,182,308,176)	246,417,526,408	(18,182,308,176)
	<b>345,695,933,744</b>	<b>(97,092,380,359)</b>	<b>404,257,621,340</b>	<b>(97,092,380,359)</b>
<b>Short-term trade receivables from related parties</b> <i>(Detailed in Note 34)</i>	<b>15,198,735,205</b>		<b>23,869,576,748</b>	

**8. SHORT-TERM ADVANCES TO SUPPLIERS**

	30/06/2025		01/01/2025	
	Balance VND	Provision VND	Balance VND	Provision VND
- Minh Long Technical Trading Limited Liability Company	2,056,000,000	-	2,056,000,000	-
- I-CODI Co., Ltd	1,348,779,000	-	1,348,779,000	-
- Others	11,213,077,577	(1,049,311,373)	14,527,168,382	(1,049,311,373)
	<b>14,617,856,577</b>	<b>(1,049,311,373)</b>	<b>17,931,947,382</b>	<b>(1,049,311,373)</b>



**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)***(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)***9. OTHER RECEIVABLES**

	<b>30/06/2025</b>		<b>01/01/2025</b>	
	<b>Balance</b>	<b>Provision</b>	<b>Balance</b>	<b>Provision</b>
	<b>VND</b>	<b>VND</b>	<b>VND</b>	<b>VND</b>
<b>Short-term</b>	<b>187,123,856,862</b>	<b>(3,049,188,956)</b>	<b>206,275,405,076</b>	<b>(3,049,188,956)</b>
- Advances to employees	2,802,548,182	(2,034,741,112)	2,810,488,794	(2,034,741,112)
- Receivables from BV Pharma Joint Stock Company (1)	141,525,565,187	-	141,525,565,187	-
- National Lung Hospital (2)	3,296,735,878	-	27,966,869,638	-
- Vimedimex 2 Pharmaceutical Joint Stock Company (3)	28,261,238,655	-	28,261,238,655	-
- Vimedimex Pharmaceutical Group Joint Stock Company (4)	2,500,000,000	-	-	-
- Other receivables	8,737,768,960	(1,014,447,844)	5,711,242,802	(1,014,447,844)
<b>Long-term</b>	<b>5,824,576,965</b>	<b>-</b>	<b>6,156,226,965</b>	<b>-</b>
- Deposits, mortgages	5,724,576,965	-	6,156,226,965	-
- Other receivables	100,000,000	-	-	-
	<b>192,948,433,827</b>	<b>(3,049,188,956)</b>	<b>212,431,632,041</b>	<b>(3,049,188,956)</b>
<b>Other receivables from related parties</b>	<b>30,761,238,655</b>		<b>28,261,238,655</b>	
<i>(Detailed in Note 34)</i>				

(1) According to the Minutes of the Board of Directors' Meeting No. 07/2023/BB-VMD dated 13 March 2023 of Vimedimex Pharmaceutical Joint Stock Company regarding the settlement of receivables from BV Pharma Joint Stock Company, the Company decided to temporarily withhold the floor area of 486.46 square meters corresponding to the investment contribution of the investor group consisting of BV Pharma Joint Stock Company and relatives of Mr. Nguyen Tien Hung, Chairman of the Board of Management of BV Pharma Joint Stock Company, who have not yet fully contributed their capital to the Citilight Building Project at 45 Vo Thi Sau Street, District 1 (former), Ho Chi Minh City, until BV Pharma Joint Stock Company settles all outstanding liabilities with Vimedimex Pharmaceutical Joint Stock Company.

(2) The receivables related to two business cooperation projects with the National Lung Hospital, including:

- Joint Venture Contract No. 242/HDL/D/2013 dated April 17, 2013, and Addendum No. 01/PLHD/2014 (2014) regarding the establishment of a High-Tech Cancer Radiotherapy Center for the diagnosis and treatment of patients;

- Joint Venture - Cooperation Contract No. 242/HDL/DLK/2015 dated December 24, 2015, regarding the construction and operation of the High-Tech On-Demand Medical Treatment Center at the National Lung Hospital, which provides medical examination and treatment services with quality and pricing suitable to patients'

**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)***(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)***9. OTHER RECEIVABLES (CONT'D)**

payment capacity. The Company and the National Lung Hospital agreed to share the business results of the two projects based on profit after deducting 2% of corporate income tax and general expenses. The project duration is 50 years.

(3) The receivable related to the business cooperation results of the CEVPharma e-commerce trading platform in 2023 with Vimedimex 2 Pharmaceutical Joint Stock Company, as the entire business result for 2023 was recorded at Vimedimex 2 Pharmaceutical Joint Stock Company.

(4) The receivable related to payments to shareholders from capital contribution proceeds of the High-Tech Medical Examination and Treatment Center at the National Lung Hospital.

**10. INVENTORIES**

	30/06/2025		01/01/2025	
	At cost VND	Provision VND	At cost VND	Provision VND
- Goods in transit	306,180,786	-	-	-
- Raw materials	97,112,500	(97,112,500)	97,112,500	(97,112,500)
- Work on progress	179,533,349	(179,533,245)	179,533,349	(179,533,245)
- Merchandise goods	82,866,499,916	(4,425,383,142)	89,529,463,793	(4,665,636,623)
	<b>83,449,326,551</b>	<b>(4,702,028,887)</b>	<b>89,806,109,642</b>	<b>(4,942,282,368)</b>



**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**11. TANGIBLE FIXED ASSETS**

	Building, properties	Machinery, equipments	Transportation vehicles	Office administrative equipments	Perennial garden	Others	Total
	VND	VND	VND	VND	VND	VND	VND
<b>COST</b>							
01/01/2025	78,940,672,640	83,333,915,310	20,778,180,707	15,921,323,123	152,810,137	2,905,501,433	202,032,403,350
- Purchased	583,234,261	-	-	185,112,000	-	-	768,346,261
- Other discounts	-	-	-	(31,500,000)	-	-	(31,500,000)
30/06/2025	79,523,906,901	83,333,915,310	20,778,180,707	16,074,935,123	152,810,137	2,905,501,433	202,769,249,611
<b>ACCUMULATED DEPRECIATION</b>							
01/01/2025	29,425,619,705	66,561,266,209	10,963,576,229	15,206,702,998	152,810,137	2,846,141,517	125,156,116,795
- Depreciation	1,343,972,264	2,704,058,444	994,758,865	471,970,958	-	9,286,446	5,524,046,977
30/06/2025	30,769,591,969	69,265,324,653	11,958,335,094	15,678,673,956	152,810,137	2,855,427,963	130,680,163,772
<b>CARRYING AMOUNT</b>							
01/01/2025	49,515,052,935	16,772,649,101	9,814,604,478	714,620,125	-	59,359,916	76,876,286,555
30/06/2025	48,754,314,932	14,068,590,657	8,819,845,613	396,261,167	-	50,073,470	72,089,085,839

The cost of tangible fixed assets as at 30 June 2025 that have been fully depreciated but are still in use: VND 63,251,577,565 (as at 01 January 2025: VND 57,575,018,013).

**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)

**12. INTANGIBLE FIXED ASSETS**

Items	Land use rights VND	Copyrights, computer software VND	Licenses and Franchise Licenses VND	Total VND
<b>COST</b>				
01/01/2025	21,846,822,855	19,194,812,102	4,760,000,000	45,801,634,957
30/06/2025	21,846,822,855	19,194,812,102	4,760,000,000	45,801,634,957
<b>ACCUMULATED AMORTIZATION</b>				
01/01/2025	5,710,302,342	6,743,330,753	1,520,555,563	13,974,188,658
- Amortization during the period	238,960,239	1,669,387,120	793,333,334	2,701,680,693
30/06/2025	5,949,262,581	8,412,717,873	2,313,888,897	16,675,869,351
<b>CARRYING AMOUNT</b>				
01/01/2025	16,136,520,513	12,451,481,349	3,239,444,437	31,827,446,299
30/06/2025	15,897,560,274	10,782,094,229	2,446,111,103	29,125,765,606

The cost of intangible fixed assets as at 30 June 2025 that have been fully depreciated but are still in use: VND 2,898,859,830 (as at 01 January 2025: VND 2,817,083,830).



For the period from 01/01/2025 to 30/06/2025

**NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)*

**13. INVESTMENT PROPERTY**

Items	Land Use Right VND	Building, Properties VND	Total VND
<b>COST</b>			
01/01/2025	59,568,178,831	43,759,033,257	103,327,212,088
30/06/2025	59,568,178,831	43,759,033,257	103,327,212,088
<b>ACCUMULATED AMORTISATION</b>			
01/01/2025	16,155,560,193	26,429,354,270	42,584,914,463
- Depreciation during the period	658,211,920	807,777,500	1,465,989,420
30/06/2025	16,813,772,113	27,237,131,770	44,050,903,883
<b>CARRYING AMOUNT</b>			
01/01/2025	43,412,618,638	17,329,678,987	60,742,297,625
30/06/2025	42,754,406,718	16,521,901,487	59,276,308,205

Investment properties comprise a portion of the building and the land use rights located at 246 Cong Quynh Street, District 1 (former), Ho Chi Minh City, and the building at 45 Vo Thi Sau Street, Da Kao Ward, District 1 (former), Ho Chi Minh City, which are being leased out.

The Company has not determined the fair value of the investment properties as at the end of the reporting period because the current regulations do not provide specific guidance on the determination of the fair value of investment properties.

**14. CONSTRUCTION IN PROGRESS**

	30/06/2025 VND	01/01/2025 VND
<b>Fixed Asset Purchase</b>	<b>1,981,270,000</b>	<b>1,981,270,000</b>
- Development of ERP System Software	1,060,000,000	1,060,000,000
- Cost of constructing and developing the CEVPhamar platform	507,150,000	507,150,000
- Cost of developing other software systems	414,120,000	414,120,000
<b>Basic construction</b>	<b>32,676,951,377</b>	<b>31,923,616,333</b>
- Project 18 Hoang Van Thu, Da Lat (*)	27,637,379,453	26,884,044,409
- Project Transaction Office in Can Tho City	4,604,803,168	4,604,803,168
- Other Projects	434,768,756	434,768,756
	<b>34,658,221,377</b>	<b>33,904,886,333</b>

(\*): Investment project to build the Research Center for Conservation and Development of Medicinal Herbs in the Central Highlands at No. 18 Hoang Van Thu, Ward 5, Da Lat City, Lam Dong Province (now No. 18 Hoang Van Thu, Cam Ly Ward - Da Lat, Lam Dong Province) according to the Investment and Business Cooperation Contract signed between the Company and Thao Nguyen Real Estate Investment Joint Stock Company ("Thao Nguyen"). The project is implemented on an area of 51,523.99 m2 with the goal of conserving and developing Medicinal Herbs in the Central Highlands, building a facility for accommodation to serve Organizations/Individuals who want to come to research, visit, and relax to introduce the model of conservation and development of Medicinal Herbs, and develop agricultural tourism.

For the period from 01/01/2025 to 30/06/2025

**NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the accompanying financial statements)*

**14. CONSTRUCTION IN PROGRESS (CONT'D)**

According to the terms of the business cooperation contract, the Company represents the parties as the Investor. The Company's capital contribution is all assets attached to the land plot and contributes as the Project Investor. Thao Nguyen contributes the entire amount of money needed to establish and implement the Project. The cooperation profit will be divided between each party as follows: The Company receives 10% and Thao Nguyen receives 90% of the cooperation profit.

According to the agreement between the two parties, all investment costs for the Project construction and other costs arising in case the Project is not approved by the competent State agency or the project is not operated effectively will be borne by Thao Nguyen. At the time of preparing this separate financial report, the Project is still in the investment preparation stage.



**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**15. LONG-TERM INVESTMENTS**

**Held-to-maturity investments**

	30/06/2025		01/01/2025	
	Cost VND	Book value VND	Cost VND	Book value VND
<b>Held-to-maturity investments</b>				
<b>Short-term</b>				
+ Term deposits at banks	243,640,457,820	243,640,457,820	35,020,457,820	35,020,457,820
	242,580,457,820	242,580,457,820	33,960,457,820	33,960,457,820
	242,580,457,820	242,580,457,820	33,960,457,820	33,960,457,820
<b>Long-term</b>				
+ Term deposits at banks	1,060,000,000	1,060,000,000	1,060,000,000	1,060,000,000
	1,060,000,000	1,060,000,000	1,060,000,000	1,060,000,000

**Equity investments in other entities**

	30/06/2025		01/01/2025	
	At cost VND	Provision VND	At cost VND	Provision VND
<b>Investment in other entities</b>				
- Vietnam Investment and Service Import Export JSC	18,730,978,694	(10,799,722,346)	18,730,978,694	(10,799,722,346)
- BV Pharma Joint Stock Company	2,185,000,000	-	2,185,000,000	-
- Nature Vietnam Pharmaceutical Joint Stock Company (*)	10,799,722,346	(10,799,722,346)	10,799,722,346	(10,799,722,346)
	5,746,256,348	-	5,746,256,348	-
	<b>18,730,978,694</b>	<b>(10,799,722,346)</b>	<b>18,730,978,694</b>	<b>(10,799,722,346)</b>

(\*): On 15 July 2019, the Board of Directors of Vimedimex Pharmaceutical Joint Stock Company approved the transfer of shares in Nature Vietnam Pharmaceutical Joint Stock Company ("Nature Pharma") to Ms. Mai Thuy Linh, under the Share Transfer Agreement No. 01/2019/HDCN dated 17 July 2019, with a total of 570,000 shares. Accordingly, the Company entered into a contract to transfer 570,000 shares of Nature Pharma to Ms. Mai Thuy Linh for a total value of VND 5,700,000,000.

As of 30 June 2025, Ms. Mai Thuy Linh had paid VND 4,700,000,000 under the share transfer agreement, while the remaining VND 1,000,000,000 had not yet been settled. Therefore, the Company has not completed the remaining share transfer procedures. Consequently, as at the date of preparation of these consolidated financial statements, the Company continues to recognize its investment in Nature Vietnam Pharmaceutical Joint Stock Company as an investment in another entity.

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**16. SHORT-TERM TRADE PAYABLES**

	30/06/2025	01/01/2025
	VND	VND
- Boehringer Ingelheim International	4,704,578,297	16,147,352,350
- DKSH Pharma Vietnam Co., Ltd	95,398,933,034	215,932,595,706
- Johnson & Johnson Co., Ltd	-	23,979,579,504
- Pierre Farbe Vietnam Co., Ltd	133,067,293,997	97,544,342,057
- Others	286,992,021,704	244,779,363,321
	<b>520,162,827,032</b>	<b>598,383,232,938</b>
<b>Short-term trade payables to related parties</b>	<b>584,125,151</b>	<b>675,727,636</b>
<i>(Detailed in Note 34)</i>		

**17. OTHER SHORT-TERM PAYABLES**

	30/06/2025	01/01/2025
	VND	VND
<b>Short-term</b>	<b>131,636,012,303</b>	<b>138,444,199,973</b>
- Trade Union Fund	10,582,842,398	10,302,791,124
- Social Insurance	32,164,210	32,164,190
- Accept short-term deposits and bets	5,916,857,640	5,916,857,640
- Vimedimex Pharmaceutical Group Joint Stock Company	88,567,745	88,567,745
- Vimedimex Pharmaceutical Joint Stock Company 2 (1)	73,830,107,019	73,830,107,019
- BV Pharma Joint Stock Company (2)	10,799,722,346	10,799,722,346
- Thao Nguyen Real Estate Investment Joint Stock Company (3)	8,500,000,000	8,500,000,000
- Thang Long Cargo Services Joint Stock Company (4)	6,000,000,000	6,000,000,000
- Ms. Mai Thuy Linh (5)	4,700,000,000	4,700,000,000
- Hoa Binh Securities Joint Stock Company (6)	6,226,043,788	2,888,946,629
- Other Payables	4,959,707,157	15,385,043,280
<b>Long-term</b>	<b>18,746,790,667</b>	<b>18,469,592,392</b>
- Accept long-term deposits and bets	18,698,350,667	18,421,152,392
- Other Payables	48,440,000	48,440,000
	<b>150,382,802,970</b>	<b>156,913,792,365</b>
<b>Other payables with related parties</b>	<b>80,144,718,552</b>	<b>76,807,621,393</b>
<i>(Detailed in Note 34)</i>		

- (1) This amount represents funds received from Vimedimex 2 Pharmaceutical Joint Stock Company, related to the investment cooperation activities between Vimedimex 2 Pharmaceutical Joint Stock Company and Vimedimex Pharmaceutical Joint Stock Company for the joint investment and operation of the international e-commerce trading platform "CEVPharma." Under this arrangement, the Company is responsible for managing and operating the trading platform. This represents a jointly controlled business activity with revenue and expense sharing. According to the agreement between the parties, the business results for 2024 are to be borne by Vimedimex Pharmaceutical Distribution Center Co., Ltd.
- (2) This represents funds transferred by BV Pharma Joint Stock Company, for which the two parties have not yet agreed on the offsetting of receivable and payable balances related to this payment. (Refer to Note 9.)



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**17. OTHER SHORT-TERM PAYABLES (CONT'D)**

This represents funds related to a business cooperation arrangement with Thao Nguyen Real Estate Joint Stock Company for the implementation of the project "Tay Nguyen Medicinal Materials Research, Conservation and Development Center" located at No. 18 Hoang Van Thu Street, Da Lat City, Lam Dong Province (formerly No. 18 Hoang Van Thu, Cam Ly Ward, Da Lat City, Lam Dong Province). *(Refer to Note 14 for project details.)*

This represents funds received from Thang Long Cargo Services Joint Stock Company ("Thang Long") under the Business Cooperation Agreement No. 37/HTDT/2017 dated 11 January 2017, for the business operation at 53 Nguyen Chi Thanh Street, Ward 9, District 5, Ho Chi Minh City (currently An Dong Ward, Ho Chi Minh City). Under this agreement, the parties agreed to jointly invest in the construction of an office and serviced apartment complex, whereby the Company contributed land-use rights and existing assets located at 53 Nguyen Chi Thanh Street, while Thang Long contributed the total investment costs for upgrading and constructing the office and serviced apartment complex.

This represents funds received from Ms. Mai Thuy Linh for the transfer of shares in Nature Vietnam Pharmaceutical Joint Stock Company. As Ms. Linh has not yet fully settled the payment under the share transfer agreement, the share transfer procedures have not been completed. *(Refer to Note 15.)*

This represents profit distributed to Hoa Binh Securities Joint Stock Company related to the investment property, which forms part of the Vimedimex Office Tower located at 246 Cong Quynh Street, Pham Ngu Lao Ward, District 1 (former), Ho Chi Minh City. This property was established under the Capital Contribution Contract No.022/2009/HD-VM-HBS between Hoa Binh Securities Joint Stock Company and Vimedimex Pharmaceutical Joint Stock Company for the construction of the Vimedimex Office Tower.

**18. SHORT-TERM ADVANCES FROM CUSTOMERS**

	30/06/2025	01/01/2025
	VND	VND
- An Khang Store	3,600,177,236	3,600,177,236
- Gigamed Pharmaceutical Co., Ltd.	17,187,282,712	1,031,998,037
- Others	5,076,551,489	5,128,091,025
	<u><u>25,864,011,437</u></u>	<u><u>9,760,266,298</u></u>

**19. SHORT-TERM ACCRUED EXPENSES**

	30/06/2025	01/01/2025
	VND	VND
- Repair costs for fixed assets	482,779,966	482,779,966
- Audit fees	315,000,000	650,000,000
- Other short-term payables	142,138,917	999,245,510
	<u><u>939,918,883</u></u>	<u><u>2,132,025,476</u></u>

**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)***(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)***20. TAX AND OTHER RECEIVABLES FROM/ PAYABLES TO THE STATE BUDGET****20.1. TAX AND OTHER RECEIVABLES FROM THE STATE BUDGET**

	01/01/2025	Tax payables	Tax	30/06/2025
	VND	VND	Paid/Deducted VND	VND
- Corporate income tax	12,965,729	341,436,744	341,436,744	12,965,729
- Personal income tax	1,127,505	-	-	1,127,505
	<u>14,093,234</u>	<u>341,436,744</u>	<u>341,436,744</u>	<u>14,093,234</u>

**20.2 TAX AND OTHER PAYABLES TO THE STATE BUDGET**

	01/01/2025	Tax payables	Tax	30/06/2025
	VND	VND	Paid/Deducted VND	VND
- Output VAT	-	13,769,293,419	13,769,293,419	-
- Corporate income tax	4,883,412,749	2,321,969,643	4,994,398,352	2,210,984,040
- Personal income tax	1,036,928,646	854,500,262	1,593,757,827	297,671,081
- Contractor tax	7,068,918	87,447,680	87,830,914	6,685,684
- Land, land rental	-	4,960,436,404	4,960,436,404	-
- Others	3,383,147	167,297,332	170,680,479	-
	<u>5,930,793,460</u>	<u>22,160,944,740</u>	<u>25,576,397,395</u>	<u>2,515,340,805</u>



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**21. OWNER'S EQUITY**

**21.1 OWNERS' EQUITY TRANSACTIONS**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
<b>Owner's equity</b>		
- Opening balance	154,402,680,000	154,402,680,000
- Closing balance	154,402,680,000	154,402,680,000

**21.2 SHARES**

	30/06/2025 Shares	01/01/2025 Shares
- Number of shares registered for issuance	15,440,268	15,440,268
- Number of shares sold public market	15,440,268	15,440,268
+ Common shares	15,440,268	15,440,268
- Number of shares outstanding	15,440,268	15,440,268
+ Common shares	15,440,268	15,440,268
* Par value of shares outstanding (VND/Share)	10,000	10,000

**21.3 FUNDS**

	30/06/2025 VND	01/01/2025 VND
- Invest and development fund	33,732,320,126	33,732,320,126
- Other funds	7,338,446,765	7,338,446,765

**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)***(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)***21. OWNER'S EQUITY (CONT'D)****21.4 STATEMENT OF CHANGES IN EQUITY**

Items	Share capital		Share premium		Development investment fund		Other funds under equity capital		Retained earnings		Non-controlling interests		Total	
	VND		VND		VND		VND		VND		VND		VND	
<b>01/01/2024</b>	<b>154,402,680,000</b>	<b>114,168,390,910</b>			<b>33,732,320,126</b>		<b>7,338,446,765</b>		<b>33,370,452,012</b>		<b>79,044,744,501</b>		<b>422,057,034,314</b>	
- Profit/loss in the year	-	-	-	-	-	-	-	-	23,193,724,901		358,931,196		23,552,656,097	
- Dividend paid	-	-	-	-	-	-	-	-	(30,880,536,000)		-		(30,880,536,000)	
- Other increase	-	-	-	-	-	-	-	-	1,793,850		-		1,793,850	
<b>31/12/2024</b>	<b>154,402,680,000</b>	<b>114,168,390,910</b>			<b>33,732,320,126</b>		<b>7,338,446,765</b>		<b>25,685,434,763</b>		<b>79,403,675,697</b>		<b>414,730,948,261</b>	
<b>01/01/2025</b>	<b>154,402,680,000</b>	<b>114,168,390,910</b>			<b>33,732,320,126</b>		<b>7,338,446,765</b>		<b>25,685,434,763</b>		<b>79,403,675,697</b>		<b>414,730,948,261</b>	
- Profit/loss in the period	-	-	-	-	-	-	-	-	9,924,727,093		(962,075,426)		8,962,651,667	
<b>30/06/2025</b>	<b>154,402,680,000</b>	<b>114,168,390,910</b>			<b>33,732,320,126</b>		<b>7,338,446,765</b>		<b>35,610,161,856</b>		<b>78,441,600,271</b>		<b>423,693,599,928</b>	

On 26 June 2025, pursuant to Resolution No. 01/2025/NQ-DHDCD-VMD of the General Meeting of Shareholders of Vimedimex Pharmaceutical Joint Stock Company, the General Meeting issued a resolution to revoke 2,284,950 VMD shares, representing 14.8% of the charter capital of Vimedimex Pharmaceutical Joint Stock Company, and to cancel the shareholder status of Ms. Nguyen Ngoc Dung, Ms. Tran Thi Doan Trang, and Mr. Tran Kien Cuong, effective from 1 January 2025. The resolution also confirmed the shareholder status of Vimedimex Pharmaceutical Group Joint Stock Company as the holder of 2,284,950 VMD shares, equivalent to 14.8% of the charter capital of Vimedimex Pharmaceutical Joint Stock Company, effective from 1 January 2025.



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**22 OFF-BALANCE SHEET ITEMS**

**Outsourced assets**

***The company signs land lease contracts at:***

- No. 53 Nguyen Chi Thanh Street, Ward 9, District 5, Ho Chi Minh City (now No. 53 Nguyen Chi Thanh Street, An Dong Ward, Ho Chi Minh City) for the purpose of production and business (office) from 2009 to 1 January 2046. The leased land area is 700.6 m<sup>2</sup>. According to this contract, the Company must pay annual land rent until the contract expires according to current regulations of the State. However, the Company has authorized all rights and obligations related to this land to Thang Long Cargo Services Joint Stock Company (Details of Business Cooperation with Thang Long Company in Note 17).
- No. 45 Vo Thi Sau Street, Da Kao Ward, District 1 (old), Ho Chi Minh City with an area of 2,692 m<sup>2</sup>, lease term until 31 December 2045 for use as a pharmaceutical trade center and office. According to this contract, the Company must pay annual land rent until the contract expires according to current regulations of the State.
- No. 18 Hoang Van Thu Street, Ward 5, Da Lat City, Lam Dong Province (now No. 18 Hoang Van Thu, Cam Ly Ward - Da Lat, Lam Dong Province) with a leased area of 51,523.99 m<sup>2</sup>, lease term until 25 December 2055 for the Company's production and business activities. According to this contract, the Company must pay annual land rent until the contract expires according to current regulations of the State.
- Ta Nung Commune, Da Lat City, Lam Dong (now Cam Ly Ward - Da Lat, Lam Dong Province) with an area of 83,198.9 m<sup>2</sup> of specialized land and agricultural land, land lease term of 50 years from 3 December 1993. According to this contract, the Company must pay annual land rent from 26 March 2010 until the due date according to current regulations of the State.

***The Company signs contracts to lease assets on land at:***

- Renting a house and land at No. 36/212B Truong Tho Ward, Thu Duc District, Ho Chi Minh City (now Thu Duc Ward, Ho Chi Minh City) for office and business production purposes from 1 January 2023 to 31 December 2027 (5 (five) years) according to the Property and Land Lease Contract at No. 36/212B Truong Tho Ward, Thu Duc District (now Thu Duc Ward, Ho Chi Minh City) No. 075/HD-TT dated 25 April 2024. The area of the leased land is 11,064.4 m<sup>2</sup>. The land rental price is fixed throughout the lease term.
- The Company signed a contract to lease State-owned property, Villa No. 18 Hoang Van Thu, Ward 5, Da Lat City (with a total usable area of 642.56 m<sup>2</sup> from 10 April 2019 to 10 April 2069 for repair and renovation for production and business purposes. The land rental price is adjusted every 5 years according to the price regulated by the Provincial People's Committee at the time of implementation of each new cycle.
- Lease of warehouse at Lot 38, Street 36, Quang Minh Industrial Park, Me Linh District, Hanoi, from DKSH Vietnam Co., Ltd., for the purpose of office use, storage, and preservation of trading products. The lease term is from 15 November 2022 to 14 November 2027, with a total leased area of 6,428.16 square meters of warehouse space and 94.55 cubic meters of cold storage. The rental rate is fixed for the first year of the lease term and is subject to an annual 6% increase compared to the rental rate of the immediately preceding year.
- Lease of warehouse at No. 18 L1-2 VSIP II, Street No. 3, Vietnam – Singapore Industrial Park II, Phu Hoa Ward, Thu Dau Mot City, Binh Duong Province, from DKSH Vietnam Co., Ltd., for the purpose of office use, storage, and preservation of trading products. The lease term is from 13 December 2019 to 31 December 2025, with a total leased area of 6,140.88 square meters. The rental rate is subject to an annual 5% increase compared to the rental rate of the immediately preceding year.

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**23 REVENUE FROM SALE OF GOODS AND RENDERING OF SERVICES**

	<b>From 01/01/2025 to 30/06/2025</b>	<b>From 01/01/2024 to 30/06/2024</b>
	<b>VND</b>	<b>VND</b>
- Revenue from sales of merchandises	479,755,906,997	535,772,563,291
- Revenue from cooperation contracts	20,073,698,728	23,998,871,016
- Revenue from providing services and trading in investment real estate	44,388,484,247	54,123,520,365
	<b>544,218,089,972</b>	<b>613,894,954,672</b>

**24 DEDUCTIONS**

	<b>Từ 01/01/2025 đến 30/06/2025</b>	<b>Từ 01/01/2024 đến 30/06/2024</b>
	<b>VND</b>	<b>VND</b>
Revenue deductions	7,450,304,812	622,629,178
+ Sales returns	7,450,304,812	622,629,178

**25 COST OF GOODS SOLD**

	<b>From 01/01/2025 to 30/06/2025</b>	<b>From 01/01/2024 to 30/06/2024</b>
	<b>VND</b>	<b>VND</b>
- Cost of goods sold	443,023,050,056	506,387,909,719
- Cost of business cooperation contract	23,216,323,409	23,973,064,151
- Cost of providing services, real estate investment business	24,845,684,316	26,116,584,389
	<b>491,085,057,781</b>	<b>556,477,558,259</b>

**26 FINANCIAL INCOME**

	<b>From 01/01/2025 to 30/06/2025</b>	<b>From 01/01/2024 to 30/06/2024</b>
	<b>VND</b>	<b>VND</b>
- Interest from deposits or loans	5,335,274,180	2,806,130,736
- Dividends, distributed profits	172,500,000	402,500,000
- Foreign exchange revaluation gains	16,258,853	8,880,105
	<b>5,524,033,033</b>	<b>3,217,510,841</b>



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**27 FINANCIAL EXPENSES**

	<b>From 01/01/2025 to 30/06/2025 VND</b>	<b>From 01/01/2024 to 30/06/2024 VND</b>
- Interest expense	-	2,281,941,510
- Foreign exchange loss	3,095,733,665	4,105,012,080
	<b>3,095,733,665</b>	<b>6,386,953,590</b>

**28 SELLING EXPENSES, GENERAL AND ADMINISTRATIVE EXPENSES**

	<b>From 01/01/2025 to 30/06/2025 VND</b>	<b>From 01/01/2024 to 30/06/2024 VND</b>
<b>Selling expenses</b>	<b>36,015,675,230</b>	<b>37,557,200,119</b>
- Labour costs	10,764,682,507	12,012,997,832
- Cost of raw materials and packaging	207,530,985	22,136,173
- Depreciation of fixed assets	3,709,949,281	192,233,344
- Expenses for outsourced services	20,604,620,070	24,180,552,353
- Others	728,892,387	1,149,280,417
<b>General and administrative expenses</b>	<b>10,561,744,881</b>	<b>9,019,763,800</b>
- Management personnel costs	6,834,891,862	4,937,169,478
- Tools, equipment, and supplies costs	209,077,135	41,136,167
- Depreciation of fixed assets	1,348,733,689	1,274,650,590
- Taxes, fees, and charges	1,200,155,568	61,082,334
- Provision costs/(Reversal)	(2,566,660,193)	(100,000,000)
- Outsourced service costs	1,687,812,160	1,228,225,610
- Others	1,847,734,660	1,577,499,621
	<b>46,577,420,111</b>	<b>46,576,963,919</b>
<b>Selling expenses and general and administrative from related parties</b> <i>(Detailed in Note 34)</i>	<b>984,619,786</b>	<b>1,888,081,764</b>

**29 OTHER EXPENSES**

	<b>From 01/01/2025 to 30/06/2025 VND</b>	<b>From 01/01/2024 to 30/06/2024 VND</b>
- Late payment penalty expenses	76,002,324	66,103,046
- Others	218,598,772	3,530,957
	<b>294,601,096</b>	<b>69,634,003</b>

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**30 OPERATING EXPENSES BY NATURE**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
- Raw materials, consumables and supplies	23,131,453,860	195,521,166
- Labor costs	18,268,218,452	22,036,390,769
- Fixed asset depreciation and goodwill distributed	6,168,649,870	9,302,338,632
- Provision expense	30,435,777,439	48,569,161,675
- Other expenses in cash	19,201,988,408	16,623,033,322
	<b>97,206,088,029</b>	<b>96,726,445,564</b>

**31 CURRENT CORPORATE INCOME TAX EXPENSE**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Current CIT expenses at the parent company	1,934,776,164	674,602,029
Current CIT expenses at the subsidiary company	728,630,223	1,245,332,375
	<b>2,663,406,387</b>	<b>1,919,934,404</b>

**32 BASIC AND DILUTED EARNINGS PER SHARE**

**32.1 BASIC EARNINGS PER SHARE**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Accounting profit/loss after corporate income tax	9,924,727,093	5,271,412,072
Adjustments for accounting profits to determine profit or loss attributable to ordinary share holders	-	-
Profit attributable to ordinary share holders	9,924,727,093	5,271,412,072
Weighted average number of ordinary shares outstanding during the period	15,440,268	15,440,268
<b>Basic earnings/(loss) per share (VND/Share)</b>	<b>643</b>	<b>341</b>



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**32. BASIC AND DILUTED EARNINGS PER SHARE (CONT'D)**

**32.2 DILUTED EARNINGS PER SHARE**

	<b>From 01/01/2025 to 30/06/2025</b>	<b>From 01/01/2024 to 30/06/2024</b>
	<b>VND</b>	<b>VND</b>
Profit attributable to ordinary share holders used to calculate diluted earnings per share	9,924,727,093	5,271,412,072
Adjustments increasing or decreasing accounting profit	-	-
Profit attributable after adjustments	9,924,727,093	5,271,412,072
Number of ordinary shares outstanding during the period used to calculate diluted earnings per share	15,440,268	15,440,268
<b>Diluted earnings/(loss) per share (VND/Share)</b>	<b>643</b>	<b>341</b>

**VIMEDIMEX MEDI-PHARMA JOINT STOCK COMPANY**

8th Floor, Vimedimex Group Building, No. 46 - 48 Ba Trieu, Cua Nam Ward, Hanoi City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)***(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)***33 SEGMENT REPORTING**

The Board of Management and Board of General Directors of the Company determines that the Company's executive decisions are mainly based on the types of products and services the Company provides. Therefore, the Company's primary segment reporting is based on business sectors.

The Company's segment reporting by business sector is as follows:

**From 01/01/2025 to 30/06/2025**

	Sales of goods	Cooperated agreements with Central Lung Hospital	Investment property leasing	Total
	VND	VND	VND	VND
Net revenue from sales and service provision to external customers	472,305,602,185	20,073,698,728	44,388,484,247	536,767,785,160
<b>Total net revenue from sales and service provision</b>	<b>472,305,602,185</b>	<b>20,073,698,728</b>	<b>44,388,484,247</b>	<b>536,767,785,160</b>
Allocated expenses	443,023,050,056	23,216,323,409	24,845,684,316	491,085,057,781
<b>Segment business performance</b>	<b>29,282,552,129</b>	<b>(3,142,624,681)</b>	<b>19,542,799,931</b>	<b>45,682,727,379</b>
Expenses not allocated				46,577,420,111
Profit from business operation				(894,692,732)
Financial income				5,524,033,033
Financial expenses				3,095,733,665
Other income				10,387,052,514
Other expenses				294,601,096
Current corporate income tax				2,663,406,387
<b>Profit after corporate income tax</b>				<b>8,962,651,667</b>
Assets not allocated				1,133,014,474,432
<b>Liabilities not allocated</b>				<b>707,397,414,564</b>



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**34 TRANSACTIONS AND BALANCES WITH RELATED PARTIES**

**The income and salary of the members of the Board of Management, Board of General Directors and Board of Supervisors are as follows:**

	<b>Position</b>	<b>From 01/01/2025 to 30/06/2025 VND</b>	<b>From 01/01/2024 to 30/06/2024 VND</b>
<b>Board of Management</b>		<b>846,086,956</b>	<b>720,000,000</b>
- Mr. Le Xuan Tung	Chairman	240,000,000	240,000,000
- Mr. Trinh Thanh Giang	Vice Chairman	240,000,000	240,000,000
- Ms. Tran My Linh	Member	120,000,000	120,000,000
- Mr. Le Tien Dung	Member	120,000,000	120,000,000
- Mr. Le Tri Dung	Member	120,000,000	-
- Mr. Nguyen Minh Son	Member (Appointed on 26 June 2025)	3,043,478	-
- Mr. Nguyen Phan Trung Kien	Member (Appointed on 26 June 2025)	3,043,478	-
<b>Board of General Director</b>		<b>632,140,200</b>	<b>400,000,000</b>
- Ms. Tran My Linh	General Director	226,080,900	220,000,000
- Ms. Do Thi Dong	Deputy General Director	-	-
- Mr. Be Cong Son	Deputy General Director	-	-
- Mr. Nguyen Bao Anh	Deputy General Director	115,059,300	180,000,000
- Mr. Le Tri Dung	Deputy General Director	120,000,000	-
- Mr. Nguyen Anh Tuan	Deputy General Director (Appointed on 07 March 2025)	171,000,000	-
<b>Board of Supervisors</b>		<b>150,760,869</b>	<b>180,000,000</b>
- Mr. Tran Hung Cuong	Chief Supervisor (Dismissed on 26 June 2025)	87,717,391	-
- Mr. Doan Duc Giang	Member (Appointed on 24 July 2025)	60,000,000	60,000,000
- Mr. Nguyen Ba Tuan	Member (Dismissed on 26 June 2025)	-	90,000,000
- Ms. Pham Thi Thu Thao	Member (Dismissed on 28 June 2024)	-	30,000,000
- Mr. Truong Duy Phong	Member (Appointed on 26 June 2025)	1,521,739	-
- Ms. Nguyen Thanh Thanh Binh	Member (Appointed on 26 June 2025)	1,521,739	-

**Other parties related to the Company include:**

<b>No.</b>	<b>Related parties</b>	<b>Relationship</b>
1	Vimedimex 2 Pharmaceutical Joint Stock Company	Major shareholder
2	Vimedimex Group Pharmacy Corporation	Parties related to board members
3	Vimedimex Hoa Binh Real Estate Company Limited	Parties related to board members
4	Hoa Binh Securities Joint Stock Company	Parties related to board members
5	Belleville Hanoi Real Estate Joint Stock Company	Parties related to board members

For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**34 TRANSACTIONS AND BALANCES WITH RELATED PARTIES (CONT'D)**

**Transactions with related parties**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
<b>Purchase of goods and services</b>	<b>984,619,786</b>	<b>1,083,081,764</b>
- Vimedimex Hoa Binh Real Estate Company Limited	984,619,786	1,083,081,764
<b>Profit sharing in business cooperation</b>	<b>6,226,043,788</b>	<b>5,051,841,066</b>
- Hoa Binh Securities Joint Stock Company	6,226,043,788	5,051,841,066

**Balances with related parties**

	30/06/2025 VND	01/01/2025 VND
<b>Trade receivables</b>	<b>15,198,735,205</b>	<b>23,869,576,748</b>
- Belleville Hanoi Real Estate Joint Stock Company	15,191,450,000	15,191,450,000
- Vimedimex 2 Pharmaceutical Joint Stock Company	7,285,205	8,678,126,748
<b>Other receivables</b>	<b>30,761,238,655</b>	<b>28,261,238,655</b>
- Vimedimex 2 Pharmaceutical Joint Stock Company	28,261,238,655	28,261,238,655
- Vimedimex Pharmaceutical Group Joint Stock Company	2,500,000,000	-
<b>Trade payables</b>	<b>584,125,151</b>	<b>675,727,636</b>
- Vimedimex Hoa Binh Real Estate Limited Liability Company	541,540,882	633,143,367
- Vimedimex 2 Pharmaceutical Joint Stock Company	42,584,269	42,584,269
<b>Other payables</b>	<b>80,144,718,552</b>	<b>76,807,621,393</b>
- Vimedimex Pharmaceutical Group Joint Stock Company	88,567,745	88,567,745
- Hoa Binh Securities Joint Stock Company	6,226,043,788	2,888,946,629
- Vimedimex 2 Pharmaceutical Joint Stock Company	73,830,107,019	73,830,107,019

**35 EVENTS OCCURRING AFTER THE END OF THE ACCOUNTING PERIOD**

As of 10 September 2025, the Ho Chi Minh City Stock Exchange (HOSE) issued Notice No. 1656/QD-SGDHCM, announcing the additional list of securities ineligible for margin trading, which included the VMD stock code.

According to the Minutes of the Board of Management's meeting No. 15/2025/BBHDQT-VMD dated 20 September 2025 of Vimedimex Pharmaceutical Joint Stock Company, the Board of Management requested the Board of General Directors to work with relevant parties to clarify matters related to certain former employees of the Company who allegedly abused their positions and authority to misappropriate assets, causing losses to Vimedimex Pharmaceutical Group Joint Stock Company, a related party of the Company:

- The fund transfers from Vimedimex Pharmaceutical Group Joint Stock Company (VMG) through Vimedimex Pharmaceutical Joint Stock Company (VMD), followed by cash withdrawals and bank transfers, totaled VND 343,738,865,391 during the period from 15 April 2021 to 30 January 2023. In addition, VMD recorded a receivable from Ms. Nguyen Ngoc Dung amounting to VND 193 billion, representing cash withdrawn in 2022 but not yet repaid *(According to the Minutes of the Board of Directors' Meeting No. 136/2024/BB-VMG dated December 31, 2024 of VMG, the Board of Directors of VMG approved that VMG would be responsible for recovering the doubtful receivable of VND 193 billion related to Ms. Nguyen Ngoc Dung on behalf of VMD, and consequently, VMD would no longer have any obligation to repay the VND 193 billion payable to VMG.)*



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**35 EVENTS OCCURRING AFTER THE END OF THE ACCOUNTING PERIOD (CONT'D)**

- The total dividend amount related to Vimedimex Pharmaceutical Joint Stock Company's (VMD) shares for 2021 and 2022, recorded in the accounts of three individuals — Ms. Nguyen Ngoc Dung, Ms. Tran Thi Doan Trang, and Mr. Tran Kien Cuong — amounted to VND 6,512,107,500, which should have been returned to Vimedimex Pharmaceutical Group Joint Stock Company. However, these individuals allegedly appropriated VND 6,512,005,000 from their personal accounts during the period from June 15, 2021 to December 9, 2022, including: Mr. Tran Kien Cuong: VND 3,131,192,000, Ms. Nguyen Ngoc Dung: VND 1,080,062,000, Ms. Tran Thi Doan Trang: VND 2,300,751,000.
- Certain individuals in executive management positions at both VMG and VMD directed cash inflows and outflows totaling VND 252,353,295,174, and instructed Mr. Nguyen Tien Manh to withdraw VND 76,978,900,000, resulting in a total loss of VND 328,400,200,202 for VMG during the period from 19 April 2021 to 24 October 2024.

On 24 October 2025, the Ho Chi Minh City Stock Exchange (HOSE) issued Decision No. 968/QĐ-SGDHCM to suspend the trading of the shares of Vimedimex Pharmaceutical Joint Stock Company (stock code: VMD), effective from 31 October 2025.

**36 OTHER INFORMATION**

**POTENTIAL ASSETS - POTENTIAL DEBTS AT CITILIGHT COURT 45 VO THI SAU**

During the pre-equitization period, Medical Import-Export Company No. II (the predecessor of Vimedimex Pharmaceutical Joint Stock Company) received capital contributions from various organizations and individuals ("the Investors") under business cooperation contracts to develop the Citilight Building Project, a pharmaceutical trading and office center located at 45 Vo Thi Sau Street, Da Kao Ward, District 1 (former), Ho Chi Minh City ("Citilight Building"). Upon completion and commencement of operation of the Citilight Building, the Company allocated floor areas to the Investors in accordance with the proportions stated in the business cooperation contracts, allowing the Investors to utilize or lease such areas. Accordingly, the Investors either directly managed and used their allocated areas, or authorized the Company to lease them out and, on a quarterly basis, received rental income corresponding to office rental proceeds after deducting management fees, land lease payments, property taxes, and insurance costs.

On 16 February 2020, the Board of Management of Vimedimex Pharmaceutical Joint Stock Company held a meeting to discuss matters related to the Citilight Building Project located at 45 Vo Thi Sau Street, Da Kao Ward, District 1 (former), Ho Chi Minh City, as documented in the Minutes of the Board of Management's meeting No. 03/2020/BB-VMD dated 16 February 2020. Based on the audited financial statements for the year ended 31 December 2007, the following information was presented:

- The total investment value in Citilight Building is VND 96,843,227,279, in which the actual capital contributed by the Investors after the Company's inspection and review is VND 51,056,056,717, accounting for 52.72% of the total capital contribution value to build Citilight Building at 45 Vo Thi Sau.
- The total area temporarily handed over to Investors under the business cooperation contract is 6,498.2 m<sup>2</sup>, the total usable floor area that Investors are entitled to according to the actual investment price of the building when finalizing the project is 5,351.24 m<sup>2</sup>; corresponding to 52.72% of the area of Citilight Building (10,150 m<sup>2</sup>). Accordingly, the capital contributed by Investors is 17.65% less than the area received.



For the period from 01/01/2025 to 30/06/2025

**NOTE TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (CONT'D)**

*(These notes are an integral part of and should be read in conjunction with the interim consolidated financial statements)*

**36 OTHER INFORMATION (CONT'D)**


On 24 February 2020, Vimedimex Pharmaceutical Joint Stock Company issued Official Letter No. 1421/2020/CV-VMD providing official information to press agencies regarding the Citilight Building at 45 Vo Thi Sau Street. The letter stated that the Company had temporarily suspended all activities related to the payment of rental fees for commercial areas at the Citilight Building at 45 Vo Thi Sau Street, as well as other activities arising from the capital contribution process for the construction of the Building, in order to review the entire capital contribution process, settlement of construction costs, allocation of floor areas, management and operation, and profit distribution of the Citilight Building. As at 30 June 2025, the outstanding payable balance to the related investors amounted to VND 159,093,490,347 (VND 139,296,511,929 as at 01 January 2025).

At present, the Company and the investors have not yet reached an agreement on the aforementioned matters. Accordingly, this event may give rise to future economic benefits and/or obligations for the Company once the Company and the investors have resolved the outstanding issues relating to capital contribution, profit distribution, and management of the Citilight Building, in accordance with the prevailing laws and regulations.

**35 COMPARATIVE FIGURES**

The comparative figures of the interim consolidated financial statements are the figures of the Company's audited financial statements for the year ended 31 December 2024 and the reviewed interim consolidated financial statements for the period from 01 January 2024 to 30 June 2024.

*Ha Noi, 30 October 2025*

  
**Tran Thi Thanh Binh**  
Preparer

  
**Nguyen Thi Thu Dung**  
Chief Accountant

  
**Tran My Linh**  
General Director

